An Investigation of the Information Seeking Behavior of Medical Oncologists in Metropolitan Pittsburgh Using a Multimethod Approach

由 Lomax, Edward C., Lowe, Henry J., Logan, Theodore F.
出版 1997

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003

由 Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.
發表在 J Clin Oncol (2020)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

由 Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
發表在 J Immunother Cancer (2018)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

由 Clark, Joseph I, Curti, Brendan, Davis, Elizabeth J, Kaufman, Howard, Amin, Asim, Alva, Ajjai, Logan, Theodore F, Hauke, Ralph, Miletello, Gerald P, Vaishampayan, Ulka, Johnson, Douglas B, White, Richard L, Wiernik, Peter H, Dutcher, Janice P
發表在 J Investig Med (2021)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

由 Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
發表在 J Immunother Cancer (2017)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (procliv...

由 Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
發表在 J Immunother Cancer (2014)

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

由 Ribas, Antoni, Chesney, Jason A, Gordon, Michael S, Abernethy, Amy P, Logan, Theodore F, Lawson, David H, Chmielowksi, Bartosz, Glaspy, John A, Lewis, Karl, Huang, Bo, Wang, Erjian, Hsyu, Poe-Hirr, Gomez-Navarro, Jesus, Gerhardt, Diana, Marshall, Margaret A, Gonzalez, Rene
出版 2012

NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept and High Dose Interleukin-2 (HD IL-2) or HD IL-2 Alone for Inoperable Stage III or IV Melanoma

由 Tarhini, Ahmad A., Frankel, Paul, Ruel, Christopher, Ernstoff, Marc S., Kuzel, Timothy M., Logan, Theodore F., Khushalani, Nikhil I., Tawbi, Hussein A., Margolin, Kim A., Awasthi, Sanjay, Butterfield, Lisa H., McDermott, David, Chen, Alice, Lara, Primo N., Kirkwood, John M.
發表在 Cancer (2018)

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

由 Weber, Jeffrey S, Gibney, Geoff, Sullivan, Ryan J, Sosman, Jeffrey A, Slingluff, Craig L, Lawrence, Donald P, Logan, Theodore F, Schuchter, Lynn M, Nair, Suresh, Fecher, Leslie, Buchbinder, Elizabeth I, Berghorn, Elmer, Ruisi, Mary, Kong, George, Jiang, Joel, Horak, Christine, Hodi, F Stephen
發表在 Lancet Oncol (2016)

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advance...

由 Chesney, Jason, Puzanov, Igor, Collichio, Frances, Singh, Parminder, Milhem, Mohammed M., Glaspy, John, Hamid, Omid, Ross, Merrick, Friedlander, Philip, Garbe, Claus, Logan, Theodore F., Hauschild, Axel, Lebbé, Celeste, Chen, Lisa, Kim, Jenny J., Gansert, Jennifer, Andtbacka, Robert H.I., Kaufman, Howard L.
發表在 J Clin Oncol (2018)

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

由 Motzer, Robert J., Rini, Brian I., McDermott, David F., Redman, Bruce G., Kuzel, Timothy M., Harrison, Michael R., Vaishampayan, Ulka N., Drabkin, Harry A., George, Saby, Logan, Theodore F., Margolin, Kim A., Plimack, Elizabeth R., Lambert, Alexandre M., Waxman, Ian M., Hammers, Hans J.
發表在 J Clin Oncol (2015)

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase...

由 Amin, Asim, Dudek, Arkadiusz Z, Logan, Theodore F, Lance, Raymond S, Holzbeierlein, Jeffrey M, Knox, Jennifer J, Master, Viraj A, Pal, Sumanta K, Miller, Wilson H, Karsh, Lawrence I, Tcherepanova, Irina Y, DeBenedette, Mark A, Williams, W Lee, Plessinger, Douglas C, Nicolette, Charles A, Figlin, Robert A
發表在 J Immunother Cancer (2015)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in advanced clear cell renal cell carcinoma

由 Voss, Martin H., Bhatt, Rupal S., Vogelzang, Nicholas J., Fishman, Mayer, Alter, Robert S., Rini, Brian I., Beck, J. Thaddeus, Joshi, Monika, Hauke, Ralph, Atkins, Michael B., Burgess, Earle, Logan, Theodore F., Shaffer, David, Parikh, Rahul, Moazzam, Nauman, Zhang, Xiaosha, Glasser, Chad, Sherman, Matthew L., Plimack, Elizabeth R.
發表在 Cancer (2019)

Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

由 Armstrong, Andrew J, Halabi, Susan, Eisen, Tim, Broderick, Samuel, Stadler, Walter M, Jones, Robert J, Garcia, Jorge A, Vaishampayan, Ulka N, Picus, Joel, Hawkins, Robert E, Hainsworth, John D, Kollmannsberger, Christian K, Logan, Theodore F, Puzanov, Igor, Pickering, Lisa M, Ryan, Christopher W, Protheroe, Andrew, Lusk, Christine M, Oberg, Sadie, George, Daniel J
發表在 Lancet Oncol (2016)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

由 Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
發表在 Cancer Immunol Immunother (2016)

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

由 Choueiri, Toni K., Vaishampayan, Ulka, Rosenberg, Jonathan E., Logan, Theodore F., Harzstark, Andrea L., Bukowski, Ronald M., Rini, Brian I., Srinivas, Sandy, Stein, Mark N., Adams, Laurel M., Ottesen, Lone H., Laubscher, Kevin H., Sherman, Laurie, McDermott, David F., Haas, Naomi B., Flaherty, Keith T., Ross, Robert, Eisenberg, Peter, Meltzer, Paul S., Merino, Maria J., Bottaro, Donald P., Linehan, W. Marston, Srinivasan, Ramaprasad
出版 2013

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma

由 McDermott, David F., Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A., Clark, Joseph I., Sosman, Jeffrey A., Dutcher, Janice P., Logan, Theodore F., Curti, Brendan D., Ernstoff, Marc S., Appleman, Leonard, Wong, Michael K.K., Khushalani, Nikhil I., Oleksowicz, Leslie, Vaishampayan, Ulka N., Mier, James W., Panka, David J., Bhatt, Rupal S., Bailey, Alexandra S., Leibovich, Bradley C., Kwon, Eugene D., Kabbinavar, Fairooz F., Belldegrun, Arie S., Figlin, Robert A., Pantuck, Allan J., Regan, Meredith M., Atkins, Michael B.
發表在 Clin Cancer Res (2014)